Martín Magaña-Aquino

Martín Magaña-Aquino

Auto-generated profile, based on publicly available information

Martín Magaña-Aquino

Hospital Regional de Alta Especialidad Dr. Ignacio Morones Prieto, San Luis Potosí, Mexico

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 April 2020 in Antimicrobial Agents and Chemotherapy
Verified
Journal Article
Open access
PDF file
NANorma A. Aréchiga-Alvarado
Norma A. Aréchiga-Alvarado
SMSusanna E. Medellín-Garibay
Susanna E. Medellín-Garibay
RMRosa del Carmen Milán-Segovia
Rosa del Carmen Milán-Segovia
AOArturo Ortiz-Álvarez
Arturo Ortiz-Álvarez
MMMartín Magaña-Aquino
Martín Magaña-Aquino
SRSilvia Romano-Moreno
Silvia Romano-Moreno
The aim of this work was to evaluate the pharmacokinetics of amikacin in Mexican patients with different renal functions receiving once-daily dosing regimens and the influence of clinical and demographical covariates that may influence the optimization of this antibiotic. A prospective study was performed in a total of 63 patients with at least one determination of amikacin plasma concentration. Population pharmacokinetic (PK) parameters were estimated by nonlinear mixed-effects modeling; validations were performed for dosing recommendation purposes based on PK/pharmacodynamic simulations. The concentration-versus-time data were best described by a one-compartment open model with proportional interindividual variability associated with amikacin clearance (CL) and volume of distribution (V); residual error followed a homoscedastic trend. Creatinine clearance (CLCR) and ideal body weight (IBW) demonstrated significant influence on amikacin CL and V, respectively. The final model [CL (liters/h) = 7.1 × (CLCR/130)0.84 and V (liters) = 20.3 × (IBW/68)2.9] showed a mean prediction error of 0.11 mg/liter (95% confidence interval, −3.34, 3.55) in the validation performed in a different group of patients with similar characteristics. There is a wide variability in amikacin PK parameters in Mexican patients. This leads to inadequate dosing regimens, especially in patients with augmented renal clearance (CLCR of >130 ml/min). Optimization based on the final population PK model in Mexican patients may be useful, since reliability and clinical applicability have been demonstrated in this study.

1 October 2013 in International Journal of Antimicrobial Agents
Verified
Journal Article
Closed access
MSMartin E. Stryjewski
Martin E. Stryjewski
SBSteven L. Barriere
Steven L. Barriere
EREthan Rubinstein
Ethan Rubinstein
FGFredric C. Genter
Fredric C. Genter
ALArnold L. Lentnek
Arnold L. Lentnek
GCG. Ralph Corey
G. Ralph Corey

1 January 2018 in Materials Science and Engineering: C
Verified
Journal Article
Closed access
EAElizabeth Alvarado-Gomez
Elizabeth Alvarado-Gomez
MPMario Perez-Diaz
Mario Perez-Diaz
DPDonato Valdez Pérez
Donato Valdez Pérez
JRJaime Ruiz-Garcia
Jaime Ruiz-Garcia
MMMartin Magaña-Aquino
Martin Magaña-Aquino
FMFidel Martinez-Gutierrez
Fidel Martinez-Gutierrez

6 November 2025 in Journal of Infection and Public Health
Verified
Journal Article
Open access
MCMaría Noemí Carnalla-Barajas
María Noemí Carnalla-Barajas
ASAraceli Soto-Noguerón
Araceli Soto-Noguerón
FSFortino Solorzano Solórzano Santos
Fortino Solorzano Solórzano Santos
MMMercedes Macías-Parra
Mercedes Macías-Parra
VDVirginia Díaz-Jiménez
Virginia Díaz-Jiménez
GEGabriela Echániz-Aviles
Gabriela Echániz-Aviles
Streptococcus pneumoniae remains a leading cause of bacterial meningitis in children, despite widespread use of pneumococcal conjugate vaccines (PCVs). This study evaluates changes in serotype distribution and antimicrobial resistance (AMR) in pediatric pneumococcal meningitis in Mexico, before and after PCV introduction. We conducted a prospective analysis of pneumococcal isolates collected from children aged 0-17 years diagnosed with meningitis between 1993 and 2024 through the GIVEBPVac surveillance network. Serotyping was performed using the Neufeld-Quellung reaction, and AMR profiles were determined by broth microdilution following CLSI guidelines. Temporal trends were assessed by Poisson regression and stratified by vaccination period (pre-PCV, PCV7/PCV10, and PCV13). A total of 575 pneumococcal meningitis isolates were analyzed. The proportion of PCV13 serotypes declined from 77.2 % in the pre-PCV period to 33.3 % in the PCV13 period, while non-vaccine serotypes rose to 66.7 %. Serotypes 14, 6B, 19 F, and 23 F were predominant before PCV introduction. In the PCV13 era, serotypes 19 A and 15B increased in frequency, while 23B and 6 C emerged among non-vaccine serotypes. Resistance to cefotaxime increased from 22.8 % in the pre-PCV to 30.4 % during the PCV13 period. The overall case fatality rate was 8 %. PCVs significantly reduced the burden of pneumococcal meningitis in Mexican children. However, the emergence of non-vaccine serotypes and the persistence of serotype 19 A highlights the need for continued surveillance and evaluation of higher-valent vaccines to inform future immunization strategies.